Comparative Pharmacology
Head-to-head clinical analysis: BREVICON 21 DAY versus LESSINA 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREVICON 21 DAY versus LESSINA 28.
BREVICON 21-DAY vs LESSINA-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) release via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Increases viscosity of cervical mucus and alters endometrial lining to impede sperm penetration and implantation.
Combination of a progestin (levonorgestrel) and an estrogen (ethinyl estradiol). Inhibits ovulation by suppressing gonadotropin release; increases cervical mucus viscosity to impede sperm penetration, and induces endometrial changes that reduce implantation likelihood.
One tablet (0.5 mg norethindrone and 0.035 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days off.
One tablet (0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol) orally once daily for 28 days, starting on the first day of menstrual cycle.
None Documented
None Documented
Norethindrone: 7-8 hours; Ethinyl estradiol: 13-17 hours. Clinical context: Steady state reached within 5-7 days; missed pills may reduce contraceptive efficacy.
Terminal elimination half-life: 18-22 hours; clinically relevant for once-daily dosing.
Urine (50-60% as metabolites, <10% unchanged); feces (30-40% as metabolites); biliary (minor).
Renal: 30% as unchanged drug and metabolites; biliary/fecal: 70% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive